Investigating the effect of vitamin D on discoid lupus erythematosus
Phase 3
- Conditions
- Discoid lupus erythematosus.Discoid lupus erythematosusL93.0
- Registration Number
- IRCT20220506054753N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Aged over 18 years
Patients with DLE whose initial diagnosis based on clinical manifestations was confirmed during a histopathological study of a skin sample sent to the pathology department
Referred to the dermatology clinic of Sina Hospital in Tabriz
Providing Informed consent
Exclusion Criteria
Systemic lupus erythematosus
Active kidney disease
Hepatitis
Malabsorption syndrome
Corticosteroid, dietary supplements and contraceptives, or anticonvulsants (phenytoin and phenobarbital) users
People with liver enzymes over 40
Abnormal sensitivity to vitamin D
Pregnant women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of discoid lupus erythematosus using CLAS criteria. Timepoint: Measurements before starting treatment and after 3 months of oral vitamin D treatment. Method of measurement: Cutaneous LE Disease Area and Severity Index (CLAS) criteria.
- Secondary Outcome Measures
Name Time Method Vitamin D levels. Timepoint: Before and after the treatment period 3 months. Method of measurement: Individuals will undergo venous blood draw from the Antecubital area after 14-14 hours of fasting. The obtained samples will be measured by vitamin D level by quantitative luminescence method.